Skip to main content
Caplight Logo









Asylia Therapeutics

Asylia Therapeutics

Private
Houston, TexasHealthcare & Life Scienceshttps://asyliatx.com/

Last Round

Grant

Aug 17, 2022

Total Funding Raised

$20.75M

Company Overview

Asylia Therapeutics is a biotechnology company that develops novel immune-modulating therapies for the treatment of cancer, autoimmune, and infectious diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologymonoclonal antibodyimmunotherapydrug discoveryoncologyheat shock protein 70HSP70antigen presentationbiopharmaautoimmune diseasepreclinical researchimmune-modulating therapydrug developmentbiotech startup

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Asylia Therapeutics Comparables

Compare Asylia Therapeutics with similar companies based on industry and business-model similarity.

Asylia Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Leukogene Therapeutics
77%
GV20 Therapeutics
77%
Corner Therapeutics
75%

Asylia Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantAug 17, 2022
Series AMay 25, 2021
GrantFeb 19, 2020

Asylia Therapeutics Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 18, 2026

    Monthly visitors grew 76% MoM.

  • May 25, 2021

    $15M round led by Sporos Bioventures

Asylia Therapeutics Filings

Explore SEC and related filing metadata, where available.

Asylia Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Asylia Therapeutics's valuation, stock price, and market status.

Is Asylia Therapeutics a public or private company?

Asylia Therapeutics is a private company.

What is the current stock price of Asylia Therapeutics?

Asylia Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is Asylia Therapeutics worth (valuation)?

Valuation information for Asylia Therapeutics is not publicly available.

Can I buy Asylia Therapeutics stock?

Asylia Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Asylia Therapeutics's last funding round?

Asylia Therapeutics's most recent funding round was Grant on August 17, 2022.

Who are the main investors in Asylia Therapeutics?

Key investors in Asylia Therapeutics include National Institutes of Health (NIH), Cancer Prevention and Research Institute of Texas.

Will Asylia Therapeutics IPO soon?

No public IPO plans have been announced for Asylia Therapeutics.

How can I track Asylia Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Asylia Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersHouston, Texas
Employee Range3
Year Founded2019
Last FundingAug 17, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?